Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial

The Lancet

Volumn 381, Issue 9870, 2013, Pages 918-929

  Smolen, Josef S ^a   Nash, Peter ^b   Durez, Patrick ^c   Hall, Stephen ^d   Ilivanova, Elena ^e   Irazoque Palazuelos, Fedra ^f   Miranda, Pedro ^g   Park, Min Chan ^h   Pavelka, Karel ⁱ   Pedersen, Ronald ^j   Szumski, Annette ^j   Hammond, Constance ^j   Koenig, Andrew S ^j   Vlahos, Bonnie ^j  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d CABRINI INSTITUTE   (Australia)

^e Leningradskaya Regional Clinical Hospital St Petersburg   (Russian Federation)

^f Hospital Angeles Mocel   (Mexico)

^g UNIVERSITY OF CHILE   (Chile)

^h Yonsei University College of Medicine   (South Korea)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE; PLACEBO;

ACUTE PYELONEPHRITIS; ADULT; ARTICLE; ASIA; AUSTRALIA; BASAL CELL CARCINOMA; BRONCHITIS; CELLULITIS; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; FEMALE; HEADACHE; HERPES ZOSTER; HUMAN; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SEPTICEMIA; SOUTH AND CENTRAL AMERICA; TREATMENT OUTCOME; TUBERCULOSIS; URINARY TRACT INFECTION;

EID: 84874983369     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61811-X     Document Type: Article

References (34)

1. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009-17.
2. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42: 1854-60.
3. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 2784-92.
4. Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009; 68: 823-27.
5. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-37.
6. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003; 30: 1138-46.
7. Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology (Oxford) 2007; 46: 975-79.
8. van der Heijde D, Landewe R, van Vollenhoven R, Fatenejad S, Klareskog L. Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheumatic Dis 2008; 67: 1267-70.
9. National Institute for Health and Clinical Excellence. Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. October, 2007. http://publications.nice.org.uk/-etanercept-and-infliximab-for-the- treatment-of-rheumatoid-arthritis-ta130 (accessed Dec 12, 2012).
10. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010; 363: 301-04.
11. Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009; 76: 350-55.
12. Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010; 69: 1636-42.
13. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010; 69: 1286-91.
14. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
15. American College of Rheumatology Rheumatoid Arthritis Clinical Trial Investigators Ad Hoc Task Force. American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010. Arthritis Rheum 2011; 63: 2151-56.
16. Montag K, Gingold M, Boers A, Littlejohn G. Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice. Intern Med J 2011; 41: 450-55.
17. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
18. Knevel R, Schoels M, Huizinga TW, et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69: 987-94.
19. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-86.
20. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010; 69: 638-43.
21. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
22. O'Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2010; 69: 1823-26.
23. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60: 2272-83.
24. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374: 210-21.
25. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805-11.
26. de Croon EM, Sluiter JK, Nijssen TF, Dijkmans BA, Lankhorst GJ, Frings-Dresen MH. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2004; 63: 1362-67.
27. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82.
28. Klarenbeek NB, Koevoets R, van der Heijde DM, et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis 2011; 70: 1815-21.
29. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010; 69: 1129-35.
30. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 114: 865-76.
31. Kiely P, Walsh D, Williams R, Young A. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity-the early RA network (ERAN). Rheumatology (Oxford) 2011; 50: 926-31.
32. Smolen J, Emery P, Ferraccioli G, et al. Efficacy, safety, and improvements in work productivity and daily activities with certolizumab pegol after incomplete response to disease-modifying anti-rheumatic drugs in patients with low to moderate disease activity. Arthritis Rheum 2011; 63 (suppl 10): 2214 (abstr).
33. Smolen JS, Fleischmann R, Emery P. The OPTIMA study of methotrexate and adalimumab: 78-week outcomes in early rheumatoid arthritis patients based on achieving a low DAS28 target after 26 weeks. Ann Rheum Dis 2011; 70 (suppl 3): 259.
34. Sokka T, Kautiainen H, Pincus T, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 2009; 68: 1666-72.